Perspectives on Key MS Data From the Annual Neurology Meeting

Slides:

Advertisements

Similar presentations

Dimethyl Fumarate and Peginterferon b-1a: New Insights Into the Pivotal Trials Pavan Bhargava, MD Johns Hopkins University School of Medicine, Baltimore,

Advertisements

UK clinical perspective on treatment reviews of multiple sclerosis therapies Alasdair Coles Neurologist, Cambridge, UK.

FREEDOMS II TRIAL.

By Matthew Sampson. Overview What is it? Previous Treatments Monoclonal Antibodies Chimeric Molecules Oral Therapies Hematopoietic Stem Cells Future.

© 2014 Direct One Communications, Inc. All rights reserved. 1 Controversies in the Treatment of Multiple Sclerosis Sara S. Qureshi, MD The University of.

RIS CIS CDMS SPMS Long-term disability progression

Introduction. Practical Perspectives in the Surgical Management of Parkinson Disease: LCIG.

NEDA epoch analysis of patients with relapsing multiple sclerosis treated with ocrelizumab: Results from the OPERA I and OPERA II, phase III studies G.

Conference Series LLC Conferences

Multiple Scleroris Lyle Wiemerslage, PhD.

Applying the New Multiple Sclerosis Guidelines to Clinical Practice

Multiple sclerosis: Oral Therapies and Beyond

The Nurse View.

Highlights From the 2015 European Multiple Sclerosis Meeting

Highlights From the 2017 Annual European MS Meeting

NOACs for Cancer-Associated Thrombosis:

Pharmacy Perspectives in Multiple Myeloma: Relapsed and/or Refractory Disease.

Perspectives on Key MS Data From the Annual European MS Meeting

MS Highlights From the 2017 Annual Neurology Meeting

Program Goals Teriflunomide: Pooled Safety Data.

Challenges in the Diagnosis of MS: Physician and Nurse Perspectives

Immune Reconstitution in MS:

What Predicts Disability Progression in Multiple Sclerosis?

Applying Real-World Evidence in MS: Reviewing the State of the Art

Emerging Data and Clinical Advances in MS:

What Comes Second?.

What’s the Big Deal About Brain Atrophy and Neurodegeneration in RRMS?

T-Cell Directed Therapy in MS

Surveying the Safety of NOACs in the Real World

A Focus on Polycythemia Vera for Nurse Practitioners and Physician Assistants.

Assessing Disease Progression in MS Treatment

Oral vs IV High-Dose Methylprednisolone Are Equally Effective in MS

Novel Therapies for the Treatment of MS

VTE Treatment Conventional Approach

Multidisciplinary Perspectives on Interstitial Lung Diseases

What Is the Role of Injectables in the Modern Era of MS Treatment?

Charting Progress in MS Treatment:

Advancing the Treatment of IBD With Biologics

Treating to Target in MS

Treatment of Thromboembolic Disease The Need for Multiple Perspectives

Improving Outcomes in Psoriatic Arthritis

Introduction to AD. Practical Approaches to the Identification of Alzheimer Disease in Primary Care.

Program Goals Overview Is NEDA a Reasonable Target?

Expert Perspectives on New Data in Multiple Sclerosis From the 2018 European MS Meeting.

Opportunistic Infections in MS What Is the Risk?

Pediatric Multiple Sclerosis: The Dawn of a New Era?

Clinical Pearls on Hot Topics in MS

NEDA 2-Year Endpoint: Not a Predictor of Long-Term Stability?

Managing Pulmonary Embolism Posthospital Discharge

Proteasome Inhibitors and Patients

Real-World Evidence: What Is It and Why Is It so Important In MS?

Reducing Risk for CV Outcomes

Emerging Multiple Sclerosis Therapies

A Multidisciplinary Perspective on the Management of Hypoparathyroidism.

Program Goals Overview Natalizumab Natalizumab: Recent Label Changes.

Secondary Progressive Multiple Sclerosis: What Do We Know and Where Are We Heading?

Program Goals Overview Is NEDA a Reasonable Target?

Oral Therapies in MS.

Novel Therapeutics in MS

Optimizing Outcomes for Patients With Systemic Lupus Erythematosus: Key Considerations.

AMD Therapy: Where Are We Now and Where Are We Going?

VTE Treatment and Secondary Prevention VTE Treatment Trials Initial Dosing.

PAH Pathways: What Do the Data Tell Us?”

Mitigating Infection Risk With DMT in MS

The ABCs of Therapeutic Strategies in Pregnancy and Multiple Sclerosis

MS, Age, and Immune Function

Updates in Progressive MS

Uncovering the Right Sequence

Selective Immunomodulation in MS

Psoriatic Arthritis.

Presentation transcript:

Perspectives on Key MS Data From the Annual Neurology Meeting

Introduction

Alemtuzumab

CARE MS II Extension: Efficacy

CARE MS II Extension: Safety

CAMMS223 Extension

DMF: ENDORSE

ENDORSE: Efficacy

DR-DMF and Lymphopenia

DMF and Lymphopenia

Perspectives on Key MS Data From the Annual Neurology Meeting

Vitamin D in CIS

Modifiable Risk Factors: Smoking

Mindfulness and MS

Network-Based Cognitive Rehabilitation in RRMS

Computer-Assisted Attention Rehabilitation

Arbaclofen in Spasticity Treatment

Perspectives on Key MS Data From the Annual Neurology Meeting

The Effect of Ocrelizumab on MRI Measures: OPERA I and II

Teriflunomide and BVL: Few Relapses

Teriflunomide and BVL: Greater Relapses

BVL in DEFINE, CONFIRM, and ENDORSE

CARE-MS I and II Extension Trials: BVL

Perspectives on Key MS Data From the Annual Neurology Meeting

OPERA I and OPERA II: Efficacy of Ocrelizumab Compared With IFN beta-1a

Ocrelizumab Safety Data

ORATORIO: Ocrelizumab in Progressive MS

Neurophysical Composite Outcome From the DECIDE Study

ASCEND: Natalizumab in Progressive MS

SYNERGY: Remyelination With Anti-LINGO-1

Abbreviations

Abbreviations (cont)

Abbreviations (cont)